Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy

Table 2

Changes in the lipid profile and blood pressure levels in 34 patients undergoing anti-TNF-alpha-adalimumab therapy due RA refractory to conventional DMARDs.

Variable	Day 0		Month 12		Day 0 versus month 12
	Mean	±SD	Mean	±SD	𝑃
Total cholesterol (mg/dL)	206.1	±33.5	208.2	±40.7	0.94
LDL-cholesterol (mg/dL)	125.4	±4.8	124.8	±38.8	0.90
HDL-cholesterol (mg/dL)	60.4	±15.8	61.8	±14.7	0.96
Atherogenic index	3.61	±1.03	3.51	±0.98	0.73
Triglycerides (mg/dL)	101.6	±5.5	108.7	±4.1	0.31
Systolic blood pressure (mmHg)	136.0	±17.8	126.9	±18.2	0.10
Diastolic blood pressure (mmHg)	81.6	±9.6	79.2	±11.6	0.36